Vanda Pharmaceuticals Inc. (VNDA)

From the record

Vanda Pharmaceuticals Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Vanda Pharmaceuticals Inc.'s 10 filed years say what it did: revenue went from $146 million in fiscal 2016 to $216 million in fiscal 2025, up 4.5% a year; it rose in 7 of 9 years; the deepest fall was 28% from fiscal 2021 to fiscal 2023; net income was positive in 6 of 10 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Vanda Pharmaceuticals Inc. lost about 67 cents for every dollar of shareholders' money. Leverage: it owed about 33 cents per dollar of assets, and net share issuance: its share count grew 1.3% over the year (the filed statements).

From the record

Vanda Pharmaceuticals Inc.'s standing among 315 graded names in its industry family: revenue of $216 million in fiscal 2025 ranks in the top 28% by size; a net margin of -102% ranks in the top 46%; revenue growth of -5.3% a year over the last 3 filed years ranks in the bottom 29% (its annual reports).

From the record

Vanda Pharmaceuticals Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Polymeropoulos, Mihael Hristos (President and CEO, as filed), filing under that title since 2006-04-12, 20.6 years (top 1% of its family); the 14 officers and directors filing in the last fifteen months have been on the record a median of 6.9 years (top 28%); 5 officer or director changes were reported on Form 8-K since 2023-11-13, against the 14 people in charge now (top 35%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Vanda Pharmaceuticals Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $85 million against no long-term debt tagged leaves 17.4% of its assets as net cash, bottom 35% of its family; cash from operations less capital spending is -51.1% of revenue (top 45%); research spending of 50.6% of revenue (bottom 43%) (its annual report).

From the record

Vanda Pharmaceuticals Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -5.3% a year over the last three filed years against 4.5% over all 10, slowing (bottom 34% of its family); the newest year grew 8.7% (top 48%); research spending grew 8.4% a year (top 41%); capital spending grew 13.7% a year (top 28%) (its annual reports). Vanda Pharmaceuticals Inc. reported 3 product lines in fiscal 2025: Fanapt at $117 million (54%), Hetlioz at $71 million (33%), PONVORY at $27 million (13%); 1 of 3 grew against the year before (its annual report).

From the record

Vanda Pharmaceuticals Inc.'s newest year against its own record: revenue of $216 million in fiscal 2025 came in 23% above the $176 million its prior three years' pace pointed to (top 26% of its family); net income of $220 million against a prior three-year average of $3 million (bottom 3%); a net margin of a loss larger than its revenue against -1.9% before (bottom 20%) (its annual reports).